Macquarie University, Sydney Macquarie University ResearchOnline

Showing items 1 - 15 of 18.

Add to Quick Collection   All 18 Results

Sort:
 Add All Items to Quick Collection
Date: 2016
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1108656
Description: Background: Changes in circulating tumor DNA (ctDNA) levels correlate with response to MAPK inhibitors in patients with advanced melanoma, but the utility of ctDNA as a biomarker for immunotherapy rem ... More
Reviewed: Reviewed
Date: 2016
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1109683
Description: 1 page(s)
Reviewed: Reviewed
Date: 2016
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1116843
Description: 2 page(s)
Date: 2016
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1117137
Description: Background: Pembrolizumab demonstrated superior PFS over chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) and superior OS and PFS over ipilimumab for advanced melanoma (KEYNOTE-006). Here ... More
Reviewed: Reviewed
Date: 2015
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1059720
Description: Background: The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial. Patients and methods: Chemother ... More
Reviewed: Reviewed
Date: 2015
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1059608
Description: Background: BRAF inhibitor-based therapies have been shown to induce cutaneous toxicities, with onset generally in the first 8–26 weeks of therapy. Objectives: To determine whether cutaneous toxicitie ... More
Reviewed: Reviewed
Date: 2015
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1112545
Description: Background: BRAF inhibitors (BRAFi) cause paradoxical activation of the MAPK pathway in wild-type BRAF keratinocytes resulting in cutaneous squamous cell carcinoma (cuSCC). This study examined the fac ... More
Reviewed: Reviewed
Date: 2015
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1116489
Description: Introduction: Immunotherapy with anti CTLA-4 (Ipilimumab) or anti PD-1 (Pembrolizumab, Nivolumab) antibodies are now the standard of care for metastatic melanoma and other malignancies. These drugs ha ... More
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1114378
Description: 1 page(s)
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: conference poster
Identifier: http://hdl.handle.net/1959.14/1111819
Description: 1 page(s)
Date: 2014
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1116403
Description: 2 page(s)
Date: 2014
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1114316
Description: Background: Anti-PD-1 therapy has demonstrated activity in MM however current data may not fully reflect patterns of response and relapse as discerned by comprehensive lesion-specific analysis. Method ... More
Reviewed: Reviewed
Date: 2013
Language: eng
Resource Type: conference paper
Identifier: http://hdl.handle.net/1959.14/1111872
Description: 2 page(s)
Date: 2013
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1114209
Description: Background: There is accelerated tumour growth on BRAFi cessation in BRAFi-resistant melanoma cell lines. BRAFi-treated pts have high initial response rates but progress at 6+ months. The benefit of B ... More
Reviewed: Reviewed